Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2008

View Archived Issues

Proof-of-concept study supports development of NBI-34041 for anxiety

Postmarketing study finds no increase in nonsuicide death with ziprasidone compared to olanzapine

ASF-1096 investigated in discoid and subacute lupus erythematosus

Aripiprazole data in Asperger's disorder and major depressive disorder reported

Takeda patents use of resatorvid for coronary surgical procedure complications

Pfizer initiates Japanese phase II clinical study of PF-03187207 for glaucoma

NCI files protocol for phase I/II clinical trial of Oncolytics' cancer drug Reolysin

Lundbeck begins phase I clinical studies of Lu-AA-37096 and stops development of Lu-AA-44608

GenVec makes protocol changes to phase II/III PACT trial of TNFerade for pancreatic cancer

ImmunoGen licenses exclusive right to develop IMGN-388 using Centocor antibody

Addex and Merck & Co. to codevelop drug candidate for schizophrenia

FDA approves Shire's new dosages for ADHD treatment Vyvanse

Xanthus' oral fludarabine therapy for CLL receives orphan drug designation

Recent Thallion patent discloses novel antiinfective agents

Recent Bayer patents report novel antithrombotic agents

New phase I/II trial for ispinesib monotherapy in metastatic breast cancer begins

XenoPort begins several clinical trials, gives update on other pipeline products

Amic enters license agreement with Roche Diagnostics for test for cardiac marker NT-proBNP

Takeda submits NDA for alogliptin in the U.S.

Addex announces ADX-10059 phase IIa acute anxiety data

Anti-HIV drug apricitabine enters phase III

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...